← All trials
NCT06041646
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2023
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Sep 18, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BioXcel Therapeutics IncLead sponsor
- Lotus Clinical ResearchCollaborator
- BioXcel Therapeutics IncStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.